Trial Profile
Utility of a Measure of Lupus Low Disease Activity State (LLDAS) in SLE: Pooled Analysis of the HGS1006-C1056 (BLISS-76) and HGS1006-C1057 (BLISS-52) Trials
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2019
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 19 Aug 2019 Status changed from active, no longer recruiting to completed.
- 22 Aug 2018 Planned End Date changed from 1 Aug 2018 to 1 Apr 2019.
- 22 Aug 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Apr 2019.